Bruker Corporation (BRKR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Themes - Bruker is focusing on profitability and aims to increase margins from mid-teens to low- to mid-20s over the next 3 to 5 years [2] - The company anticipates double-digit EPS growth during this period, following a significant 70% revenue increase from 2020 to 2024, despite a challenging year in 2025 [2] Strategic Investments - Bruker continues to invest in key strategic opportunities, particularly in post-genomic discovery tools for disease biology, clinical research, and drug discovery and development [3]